Peptide–drug conjugates (PDCs): a novel trend of research and ...
2023年2月1日 · Peptide–drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody–drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity.
Peptide-Drug Conjugates: A New Hope for Cancer Management
Here, we provide an overview of peptide conjugates, the better equivalents of antibody-drug conjugates, as the next generation of drugs for required precise targeting, enhanced cellular permeability, improved drug selectivity, and reduced toxicity for the efficient treatment of cancers.
Peptide-drug conjugates: A new paradigm for targeted cancer …
2024年2月5日 · Peptide-drug conjugates (PDCs) are the new hope for targeted therapy after antibody-drug conjugates (ADCs). Compared with ADCs, the core advantages of PDCs are enhanced tissue penetration, easier chemical synthesis, and lower production costs.
Peptide–Drug Conjugates: An Emerging Direction for the Next …
2024年1月26日 · Building on recent advances in peptide science, medicinal chemists have developed a hybrid class of bioconjugates, called peptide–drug conjugates, that demonstrate improved efficacy compared to peptides and small molecules independently.
Peptide-drug conjugates (PDCs): a novel trend of research and
Peptide-drug conjugates (PDCs) are the next generation of targeted therapeutics drug after antibody-drug conjugates (ADCs), with the core benefits of enhanced cellular permeability and improved drug selectivity.
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery …
2024年1月24日 · The emergence of peptide–drug conjugates (PDCs) that utilize target-oriented peptide moieties as carriers of cytotoxic payloads, interconnected with various cleavable/noncleavable linkers, resulted in the key-foundation of the new era of …
Peptides as a platform for targeted therapeutics for cancer: peptide ...
2020年12月21日 · Peptides can offer the versatility needed for a successful oncology drug discovery approach. Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present increased tumour penetration and selectivity.
Peptide Drug Conjugates and Their Role in Cancer Therapy
Peptide-drug conjugates (PDCs), a subset of drug conjugates, are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and linkers that connect the payload to the peptide.
Peptide-Drug Conjugates: A New Hope for Cancer Management
2022年10月25日 · Here, we provide an overview of peptide conjugates, the better equivalents of antibody-drug conjugates, as the next generation of drugs for required precise targeting, enhanced cellular permeability, improved drug selectivity, and reduced toxicity for the efficient treatment of cancers.
Peptide–Drug Conjugates with Different Linkers for Cancer …
2020年12月31日 · While antibody–drug conjugates (ADCs) are now clinically established for cancer therapy, peptide–drug conjugates (PDCs) are gaining recognition as a new modality for targeted drug delivery with improved efficacy and reduced side effects for cancer treatment.
Peptide–Drug Conjugates as Effective Prodrug Strategies for …
Peptide–drug conjugates (PDCs) represent an important class of therapeutic agents that combine one or more drug molecules with a short peptide through a biodegradable linker. This prodrug strategy uniquely and specifically exploits the biological ...
Progress and Future Directions with Peptide-Drug Conjugates …
2021年10月5日 · Peptides as tumor-targeting carriers in peptide-drug conjugates (PDCs) offer a number of benefits. Melphalan flufenamide (melflufen) is a highly lipophilic PDC that takes a novel approach by utilizing increased aminopeptidase activity to selectively increase the release and concentration of cytotoxic alkylating agents inside tumor cells.
Peptide-Drug Conjugates: A New Hope for Cancer Management
2022年10月25日 · Here, we provide an overview of peptide conjugates, the better equivalents of antibody-drug conjugates, as the next generation of drugs for required precise targeting, enhanced cellular permeability, improved drug selectivity, and reduced toxicity for the efficient treatment of cancers.
Research advances in peptide‒drug conjugates - ScienceDirect
2023年9月1日 · Peptide‒drug conjugates (PDCs) are drug delivery systems consisting of a drug covalently coupled to a multifunctional peptide via a cleavable linker. As an emerging prodrug strategy, PDCs not only preserve the function and bioactivity of the peptides but also release the drugs responsively with the cleavable property of the linkers.
Conjugates for use in peptide therapeutics: A systematic review …
Conjugating the peptide to an inert chemical moiety is a strategy that has repeatedly proven to be successful in extending the half-life of some therapeutics.
A Brief Guide to Preparing a Peptide–Drug Conjugate
2023年6月8日 · Schematic structure of a peptide–drug conjugate (PDC). Given the emerging interest in this type of hybrid constructs, this concept paper has the aim to give a short guide for determining the finest conjugation reaction to connect a specific drug to a particular peptide/peptidomimetic.
Peptides as a platform for targeted therapeutics for cancer: peptide ...
2020年9月30日 · Peptides can offer the versatility needed for a successful oncology drug discovery approach. Peptide–drug conjugates (PDCs) are an emerging targeted therapeutic that present increased tumour penetration and selectivity.
RGD Peptide‐Drug Conjugates as Effective Dual Targeting …
2021年4月15日 · Many examples of RGD (Arg-Gly-Asp) peptide-drug conjugates (PDCs) have been proposed as targeted drug delivery systems.
Peptide-Drug Conjugate: A Novel Drug Design Approach
The targeting therapy with antibody-drug conjugates (ADCs) and peptide-drug conjugate (PDCs), which are usually composed of monoclonal antibodies or peptides, toxic payloads and cleavage/ noncleavage linkers, has been extensively studied for decades.
Peptide Drug Conjugates and Their Role in Cancer Therapy - MDPI
2023年1月3日 · Peptide-drug conjugates (PDCs), a subset of drug conjugates, are composed of carrier peptides ranging from 5 to 30 amino acid residues, toxic payloads, and linkers that connect the payload to the peptide.
Drug-phospholipid conjugate nano-assembly for drug delivery
2024年12月22日 · As the name implies, DPCs are conjugates of drug molecules and phospholipid structures. Similar strategies are widely reported, such as drug-antibody, 8 drug-polymer, 9 drug-peptide 10 or even drug-drug conjugates, 11 of which most can be classified as prodrugs. These prodrug conjugates would be inactive before metabolism or conversion, and the ...
Chimeric Peptide-Engineered Polyprodrug Enhances Cytotoxic T …
2024年12月28日 · Tumor-specific cytotoxic T cell immunity is critically dependent on effective antigen presentation and sustained signal transduction. However, this immune response is frequently compromised by the inherently low immunogenicity of breast cancer and the deficiency in major histocompatibility complex class I (MHC-I) expression. Herein, a chimeric peptide …